Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 First participant dosed in seasonal flu Phase 2 study with ...
CureVac stock is trading sideways as of early September 2026, with investors weighing recent losses against progress in the company’s mRNA vaccine and therapeutic pipeline and looking for the next ...
The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/ Corresponding presentation slides ...
LONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today announced they have restructured their existing collaboration ...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...
When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...
CureVac's share price has plummeted over 90% in the past five years due to vaccine efficacy issues and legal disputes. The mRNA specialist was unable to develop a successful COVID vaccine, unlike ...
Acuitas said it collaborated with CureVac to develop vaccine technology CureVac accused of omitting Acuitas scientists from patent applications Nov 14 (Reuters) - Biotech company Acuitas Therapeutics ...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results